Targeting Bim via a lncRNA Morrbid Regulates the Survival of Preleukemic and Leukemic Cells

[1]  B. Ebert,et al.  Clonal hematopoiesis in human aging and disease , 2019, Science.

[2]  G. Borgstahl,et al.  BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis , 2019, Cell Research.

[3]  J. An,et al.  The chemical biology of apoptosis: Revisited after 17 years. , 2019, European journal of medicinal chemistry.

[4]  C. M. Eischen,et al.  The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome , 2019, Front. Oncol..

[5]  Modi Wang,et al.  Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice , 2019, EBioMedicine.

[6]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[7]  G. Sandusky,et al.  Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis. , 2018, Cell stem cell.

[8]  A. Strasser,et al.  BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. , 2018, Cancer cell.

[9]  Austin E. Gillen,et al.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.

[10]  Ashley P Ng,et al.  Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice , 2018, Cell Death & Differentiation.

[11]  Sean P. Brown,et al.  AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. , 2018, Cancer discovery.

[12]  E. Olejniczak,et al.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. , 2018, Cancer discovery.

[13]  P. Ekert,et al.  Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 , 2018, Leukemia.

[14]  B. Singh,et al.  BH3-only protein BIM: An emerging target in chemotherapy. , 2017, European journal of cell biology.

[15]  Alice Giustacchini,et al.  Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD–induced myeloproliferation , 2017, The Journal of experimental medicine.

[16]  A. Ashkenazi,et al.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors , 2017, Nature Reviews Drug Discovery.

[17]  J. Rinn,et al.  The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan , 2016, Nature.

[18]  C. Mason,et al.  Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. , 2015, Cancer cell.

[19]  I. Macaulay,et al.  FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors , 2013, Cell reports.

[20]  C. Civin,et al.  FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. , 2012, Cell stem cell.

[21]  Feng-Chun Yang,et al.  Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.

[22]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  L. Hood,et al.  Dysregulated gene expression networks in human acute myelogenous leukemia stem cells , 2009, Proceedings of the National Academy of Sciences.

[25]  K. Akashi,et al.  Differential Effects of the Type I Interferons α4, β, and ε on Antiviral Activity and Vaccine Efficacy1 , 2008, The Journal of Immunology.

[26]  S. Fröhling,et al.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. , 2007, Cancer cell.